Changchun Changsheng Life Sciences Limited agreed to acquire Lianyungang Huanghai Machinery Co., Ltd. (SZSE:002680) in a reverse merger transaction on June 29, 2015. LianYunGang HuangHai will divest assets and issue approximately 301.9 million shares in exchange for 100% stake in Changchun Changsheng Life Sciences. Lianyungang Huanghai will also issue 91.6 million new shares through private placement to be used for intermediary expenses and developing pillar service of Changchun Changsheng. The transaction is a restructuring plan for backdoor listing of Changchun Changsheng Life Sciences.

Upon completion, Changchun Changsheng will be absorbed into Huanghai Machinery and the latter will shift to biomedicine industry. The deal is subject to the approval of Lianyungang Huanghai Machinery's shareholders in a meeting to be held on July 16, 2015 and the approval of the China Securities Regulatory Commission. The deal was approved by the Board of Directors of Lianyungang Huanghai Machinery on June 29, 2015. As on November 6, 2015, the transaction was approved by the China Securities Regulatory Commission. On July 16, 2015, Huanghai Machinery Co., Ltd shareholders approved the deal.

Industrial Securities Co., Ltd. acted as financial advisor for Lianyungang Huanghai Machinery. V&T Law Firm acted as legal advisor for Lianyungang Huanghai Machinery. Grant Thornton Certified Public Accountants acted as an accountant for Changchun Changsheng Life Sciences Limited.

Changchun Changsheng Life Sciences Limited completed the acquisition of Lianyungang Huanghai Machinery Co., Ltd. (SZSE:002680) in a reverse merger transaction on December 15, 2015.